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The anterior pituitary gland undergoes tumourigenic changes
in response to oestrogen treatment in several breeds of rats.
We administered diethylstilbestrol (DES) to female Wistar
rats and assessed whether the expression of vascular
endothelial growth factor (VEGF) and aquaporin-1 (AQP-1)
was altered at different time points following DES adminis-
tration. In vivo magnetic resonance imaging (MRI) scans
showed that the mass index corresponding to the mid-sagit-
tal area of DES-treated pituitary was significantly higher than
the vehicle-controlled pituitary (p<0.01) at three specific
time points, accompanied by a significant reduction in body
weight. Haematoxylin and eosin (HE) staining and immuno-
histochemical analysis demonstrated that during early
stages of induction, DES increased cell proliferation and
sprouting of endothelial cells, and VEGF expression transi-
tioned from a vessel-surrounding pattern to a diffuse pat-
tern. During later stages, angiogenesis was predominant,
and VEGF expression decreased. In contrast to the early
abundant expression of VEGF,endothelial expression of AQP-
1 increased during later stages.Our data indicated a dynam-
ic scenario of biological alterations in DES-treated pituitary
tissue, in which VEGF and AQP-1 exert their functions at dif-
ferent stages of induction,and we provide novel insights into
understanding oestrogen-related tumourigenesis in the ante-
rior pituitary gland.
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M
orphological changes of the pituitary
tumour induced by oestrogen in vitro pre-
dominantly include increased cell prolifer-
ation and angiogenesis. In contrast to the large
number of studies assessing the effects of oestrogen
on mature pituitary tumour tissue, the morphologi-
cal changes and differential expression of relevant
molecules at specific stages of induction have not
been thoroughly investigated.
Angiogenesis, a condition of neovascularisation
that arises from existing vasculature, plays pivotal
roles in foetal development,injury repair,and repro-
ductive cycle regulation. Additionally, it is a prereq-
uisite for the induction of tumour growth and inva-
sion (Gimbrone et al. 1972, Gimbrone et al. 1973,
Folkman et al. 1990). Angiogenesis critically con-
tributes to tumourigenesis and invasion of pituitary
tumours, and it affects the response of these
tumours to therapeutic intervention (Goth et al.
2003). High-density vascularisation is associated
with increased invasion potential in human mamma-
ry tumours, as well as bladder and gastric neo-
plasias; thus, it contributes to a poorer prognosis
and low survival rates (Weidner et al. 1991,
Weidner et al. 1992,Maeda et al. 1995,Bochner et
al. 1995). Angiogenesis results from signalling
mediated by multiple factors (Guinebretiere,
2005);particularly vascular endothelial growth fac-
tor (VEGF), which in turn mediates the biological
effects of other growth factors. Aquaporins (AQPs)
are a family of proteins that shuttle water across
the cellular membrane, and a subset of these pro-
teins can counteract glioma-associated lactic acido-
sis by clearing glycerol and lactate from the extra-
cellular space (Warth, 2007). AQP-1 mRNA and
protein are expressed at very low levels in rat brain
primary microvascular endothelial cells, and its
expression increases with passaging (Dolman,
2005). AQP-1 has also been detected in the pitu-
itary gland and is expressed in vascular endothelial
ORIGINAL PAPER cells of the adenohypophysis and neurohypophysis
(Kuwahara,2007).However,expression of AQP-1 in
pituitary in response to oestrogen is still not clear.
In the current study, DES was intraperitoneally
administered to rats to induce chronic tumourigen-
esis in the anterior pituitary gland.
Magnetic resonance imaging (MRI) and haema-
toxylin and eosin (HE) staining were applied to moni-
tor in vivo tumour growth and morphological changes.
Electron microscopy was utilised to assess the final
ultrastructural attributes of the pituitary gland.
Immunohistochemistry was used to evaluate the
expression of VEGF and AQP-1 and their localisation
at specific stages following DES administration.
Materials and Methods
A total of 60 female Wistar rats, 3 weeks old
and weighing 70-80 g, were used. The animals
were housed with free access to tap water and
standard pellet food. They were kept at a con-
trolled temperature (24±1°C) and humidity
(55±5%), and a 12 hour day-night cycle (10
p.m.-10 a.m.) was maintained.The induction was
based on a previously published method (Zhao et
al. 2007). Rats were randomly allocated into two
groups for each time point. In the vehicle-con-
trolled group, rats were injected intraperitoneally
with sunflower seed oil (1 mL/kg, twice a week)
for 12 weeks, whereas animals in the DES group
were administered DES intraperitoneally (5
mg/kg, twice a week) for 12 weeks. The proce-
dures undertaken were in strict compliance with
the guidelines on the care and use of laboratory
animals at our institution. DES was purchased
from Sigma Chemical Co. (St Louis, MO, USA).
Anti-VEGF antibody was purchased from Boster
Biotech (Wuhan, China), and anti-AQP-1 anti-
body was purchased from Chemicon (Temecula,
CA,USA).The DES injection was prepared by dis-
solving DES powder in sunflower seed oil to
obtain a final concentration of 5 mg/mL.
MRI scanning
At week 4, week 8, and week 12, three rats were
randomly selected from each group for MRI scan-
ning.The T2WI mid-sagittal scanning technique was
used to monitor the changes in the pituitary gland
at each time point. Intraperitoneal administration
of hydration chloraldehyde at 30 mg/100 g of body
weight was applied to minimise animal movement
during scanning.The rats were placed in a specifi-
cally designed saddle-coil probe,and a GEMSL×3T
superconductive MR (General Electric, Fremont,
CA) medical imaging instrument was used to obtain
a mid-sagittal T2WI image with a TR of 3100 ms
and a TE of 115 ms. Data collection matrix sizes
were 320×288 for T2WI. The mid-sagittal section
was defined as the in-line position of the olfactory
bulb, corpus callosum, cerebellum, and brain stem.
The software Image Tool II was used to obtain the
mid-sagittal area indexed by the number of pixels
within each rat pituitary gland.
Morphological methods
At each time point, rodents were weighed and
anaesthetised by hydration chloraldehyde at 30
mg/100 g body weight and transcardially perfused
with a 40 g/L solution of paraformaldehyde diluted
in PBS (0.01 M, pH 7.4).The tissues were embed-
ded in paraffin and sectioned at 4 µm for HE stain-
ing and immunohistochemistry.
Immunohistochemical staining was applied to
demonstrate the expression and localisation of
VEGF and AQP-1. In brief, deparaffinised sections
were rehydrated through a graded series of ethanol
to phosphate buffered saline (PBS). Antigen
retrieval was performed, and endogenous peroxi-
dase clearance was performed by incubation in 3%
H2O2.Then sections were blocked with 10% normal
goat serum for 30 minutes. Afterwards, these sec-
tions were individually incubated with anti-VEGF
and anti-AQP-1 antibodies (diluted at 1:50) at 4°C
overnight. The antigen-antibody complexes were
visualised using the avidin-biotin-peroxidase com-
plex (ABC) method. Counterstaining was per-
formed with Mayer’s haematoxylin.
Transmission electron microscopy
After induction, one rat from the vehicle control
group and two rats from the DES group were ran-
domly selected for transmission electron micro-
scopic analysis. For electron microscopy, pituitary
tissues were fixed in 2% glutaraldehyde in 0.1 M
PBS (pH 7.4) and then subjected to postfixation in
2% osmium tetroxide.The tissues were embedded
in Araldite, and the ultra thin sections were exam-
ined using electron microscopy (Philips EM208).
Statistical analysis
Results were expressed as means ± standard devi-
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utilised to compare the differences between the two
groups in terms of body weight, mid-sagittal area,
with post hoc testing using the Bonferroni proce-
dure. P values less than 0.05 were considered sig-
nificant.
Results
Body weight 
Fur loss in the DES group was initially observed
as early as 2 weeks after the initiation of DES
treatment and was sustained throughout the
remainder of the study (data not shown). At weeks
4,8,and 12,the body weights in the vehicle control
group were 189.6±15.6 g, 256.4±27.0 g, and
244.5±23.8 g, respectively, whereas in the DES
group they were 164±11.4 g, 209.2±13.5 g and
208.4±21.0 g, respectively.Therefore, body weight
was significantly reduced in the DES group at each
time point (n=10 in each group, and p<0.05) com-
pared with the vehicle-controlled group.
MRI changes
At three time points,T2WI scanning of the pituitary
gland in all tested rats in the vehicle-controlled group
indicated a typical triangular pattern with sharp
margins and uniform image signal intensity lighter
than that of the surrounding brain tissue.The periph-
eral meninges and cerebral spinal fluid (CSF) were
also continuous. No abnormal changes in the shape
were observed in the vehicle-controlled group
throughout the course of the study (Figure 1 A1-3).
At week 4, the pituitary gland in the DES-treated
rats started to enlarge, losing its typical triangular
shape,and the dura mater showed heterogeneous sig-
nals under T2WI,with a blurred subarachnoid space
(Figure 1 B1). At week 8, a discontinuous dura
mater, further enlarged pituitary gland, and hetero-
geneous intrahypophyseal signal intensity were
observed (Figure 1 B2). At week 12, the pituitary
gland crept over the sella turcica in a hillock-like
shape.The continuity of the dura mater was severely
destroyed, and the enlarged pituitary gland expand-
ed into the subarachnoid space, resulting in a mal-
formed pituitary gland in the DES-treated rats
(Figure 1 B3). MRI scanning has been proved to be
a practical method for monitoring the growth and
morphological alterations of the pituitary gland
induced by oestrogen treatment,and the mid-sagittal
area closely correlates with the mass of the pituitary
gland. During the progression of these studies, the
pituitary gland in the control group exhibited slow
growth; the indexed number of pixels was 67.0±4.6,
75.7±7.6, and 88.3±3.2 at weeks 4, 8, and 12,
respectively.In contrast,the mid-sagittal areas of the
pituitary tissue in the DES-treated group were
131.0±11.5,160.7±11.7 and 315.67±11.6,respec-
tively,which was significantly higher than in the con-
trol group (n=3 in each group and p<0.01 in com-
parison to the controls) (Figure 1 C).
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Figure 1. Representative pictures showing the rat pituitary gland under mid-sagittal T2WI. In vivo MRI scanning showed that DES induced
gradual enlargement of the pituitary gland (indicated by the arrow) at 4, 8, and 12 weeks (B 1-3), in contrast to the lack of change in the
vehicle-treated pituitary (A1-3). As shown in C, long-term treatment of DES resulted in significantly larger mid-sagittal areas of the pitu-
itary gland compared with the vehicle controls (*p<0.01, compared with controls, respectively). 
CHistology and immunohistochemistry
Initially after the administration of DES,localised
cell proliferation was observed (Figure 2A), and at
8 weeks,there was further spreading of proliferative
cells. A typical characteristic of this stage is the
sprouting of spindle-like endothelial cells lining the
proliferative cells and the formation of large cord-
like structures (Figure 2B). At this stage, no vascu-
larised lumens were apparent in the area of prolifer-
ation. At week 12, vascular lakes were predominant
in the anterior pituitary gland (Figure 2C);however,
there was still a discernable borderline between
areas with and without angiogenesis.Notably,in the
area without angiogenesis, cells with condensed
nuclei were visible,which was rarely observed in vas-
cular lake-enriched areas (data not shown). Based
on the dynamic alterations observed from HE stain-
ing of DES-treated rat pituitary tissue, we found
that angiogenesis characterised by vascular lake for-
mation was a subsequent event to increased cell pro-
liferation during pituitary tumourigenesis. We
hypothesised that different factors may function
during specific stages,so we investigated the expres-
sion of VEGF, a widely accepted angiogenic growth
factor, and aquaporin-1 (AQP-1), a potential angio-
genic stimulator, in response to DES administration
over a 12-week time course. Throughout tumour
induction and progression, expression of VEGF was
weak and sparse in the vehicle-controlled group
(data not shown). We could not detect the expres-
sion of VEGF in the endothelial cells in either group
at any time point. Initially, in the DES-treated
group,cytoplasmic VEGF-positive cells were mainly
localised to the areas surrounding vessels (Figure
3A). At week 8, a diffuse expression pattern of
VEGF was observed, whereas a subset of cells
exhibited a perinuclear pattern (Figure 3B). When
angiogenesis was complete at week 12,the intensity
of VEGF expression was reduced (Figure 3C); how-
ever, VEGF-positive cells were still prevalent in
angiogenic areas in comparison to less angiogenic
areas, resulting in sharp separation of the two nich-
es (Figure 3D).Prior to the completion of angiogen-
esis, we could not recognise differential expression
of AQP-1 between the two groups (data not shown),
but by week 12, expression of AQP-1 was enhanced
in the endothelial cells that lined the vascular walls
(Figure 4). In contrast, there was no apparent
expression of AQP-1 in proliferating cells.
Transmission electron microscopy
The intracellular membrane localisation of a
secretory particle was detected in DES-treated pitu-
itary tissue at week 12 (Figure 5A).The rough endo-
plasmic reticulum (RER) was well developed into a
concentric-circled structure, a typical characteristic
for the development of prolactinoma (Figure 5B).
Concurrently, secretory granules with diameters
ranging from 100 nm to 300 nm accumulated in
areas adjacent to the vascular wall (Figure 5C).The
vascular wall surrounding neovascularised vessels
was thin and poorly developed and had endothelial
cells attached (Figure 5D).
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Figure 2. HE staining showing the morphological changes of the
pituitary tissues subjected to DES treatment at week 4 (A), week
8 (B), and week 12 (C), respectively. (Scale bars, 20 µm).57
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Figure 3. Immunostaining showing the expression of
VEGF at week 4 (A), week 8 (B) and week 12 (C and
D). Initially, expression of VEGF was localised to the
perivascular zone (A), and then its expression transi-
tioned to a diffuse pattern (B). VEGF expression was
reduced dramatically during angiogenesis (C),
although its expression in the angiogenic area still
exceeded that in the area with less angiogenesis (D)
(scale bars: A-C , 20 µm; D, 80 µm).
Figure 4. IImmunostaining for the expression of AQP-
1 in the vehicle-controlled group (A) and DES group
(B) at week 12. A weak signal of AQP-1 expression
was detected in the normal hypophyseal vascular
walls (A), and DES-induced expression of AQP-1 was
exclusively localised to the endothelial cells of neo-
vascularised vessels (B) (scale bars: A and B,20 µ µm).
Figure 5. Representative image showing the ultra-
structural results of the anterior pituitary gland treat-
ed with DES (SG: secretion granule; RER: rough endo-
plasmic reticulum; EC: endothelial cell) (scale bars:
A, 300 nm; B, C, and D, 1 µm).Discussion
Oestrogen has proven to be an efficient tumouri-
genic inducer for the pituitary gland, and several
events contribute to this process. Intraperitoneal
injection of oestrogen provided chronic tumouri-
genesis induction with real time dose modulation
according to body weight.This method facilitates
monitoring of the dynamic changes in neoplastic
growth  in vivo through MRI and immunohisto-
chemistry, enabling the identification of morpho-
logical and expression alterations.
The mid-sagittal accumulated pixel number
under T2WI highly correlated with pituitary body
mass, suggesting that it is a high fidelity tool to
evaluate rat pituitary mass in vivo (Rudin,1988).
Van Nesselrooij (van Nesselrooij, 1992) found
that MRI could detect enlarged pituitary glands
in rats as early as 16 days after treatment with
estradiol-17. Our results showed that DES accu-
mulation correlated with increased mid-sagittal
area, which reached its peak at week 12, suggest-
ing increased pituitary volume and mass.
MRI investigation also detected a blurred and
discontinuous CSF signal representing the nar-
rowing of the interstitial space between the pitu-
itary tissue and dura mater at week 12.This sug-
gests that enlargement of pituitary tissue may
oppress adjacent structures such as the dura
mater and pons.
In previous studies, non-canonical proliferation
of pituitary cells that occurred with the emer-
gence of blood-enriched space was defined as a
pituitary tumour (Satoh, 1997). In our study, in
vivo MRI test and HE staining provided detailed
information on the dynamic morphological
changes that occurred during tumourigenesis of
the pituitary gland.The pituitary cell proliferation
transitioned from a local pattern to a diffuse pat-
tern with the development and completion of neo-
vascularisation. Angiogenesis was apparent at
week 12,which may have contributed to the rapid
increase in volume of the pituitary gland, as con-
firmed by MRI at week 12.
The dynamic morphological changes led us to
hypothesise that specific growth factors may be
expressed in a distinct pattern during pituitary
tumourigenesis. To assess this, we performed
immunostaining for VEGF, a widely accepted key
regulator of angiogenesis,and AQP-1,a candidate
stimulator of angiogenesis, proliferation and
metastasis.VEGF,a homodimeric heparin-binding
affinity protein with a molecular weight of 45
kDa, was initially extracted from bovine pituitary
follicular cells by Gospodarowicz et al.
(Gospodarowicz, 1989). VEGF interacts with its
receptor to signal in a paracrine fashion, specifi-
cally exerting mitogenic effects on nearby
endothelial cells. Additionally,VEGF can increase
the osmotic ability of the vascular endothelia,
leading to the extravasation of serum proteins,
fibre sedimentation, damage to the blood-brain-
barrier due to enhanced endothelial proliferation.
VEGF expression was detected under conditions
of ischaemia, anoxia, high blood sugar levels, and
hormone exposure. VEGF expression has been
observed in rat and human growth hormone (GH)
pituitary tumours, prolactinoma, and adrenocor-
ticotropic hormone (ACTH) adenoma, which can
be stimulated by transformation factors including
oestrogen and inhibited by dexamethasone
(Loyhrer, 2001). In the normal pituitary gland,
expression of VEGF was mainly restricted to
endothelial cells, but here, we detected expression
of VEGF in proliferative pituitary cells, but not in
endothelial cells. This is consistent with Pan’s
report that VEGF was strongly expressed in pitu-
itary adenomas and correlated with the tumour
grade (Pan, 2003). Banerjeei et al. (Banerjeei,
2000) determined that methoxyestradiol could
downregulate  VEGF expression and potentially
inhibit tumour growth by reducing expression of
the pituitary tumour transforming gene (PTTG)
(McCabe, 2002; Heaney, 2002).
Expression of VEGF was initially limited to
areas surrounding the vessels. We hypothesise
that these cells initially sensitise and react to the
stimulation of DES by upregulating the expres-
sion of VEGF because they are in direct contact
with the vascular wall. At week 8, VEGF was
expressed in a diffuse pattern due to continuous
stimulation of DES.Notably,perinuclear localisa-
tion of VEGF was noted in a subset of prolifera-
tive cells. The nuclear localisation of VEGF was
additionally confirmed by immune electron
microscopy,which indicated that VEGF associates
with the nucleolus and euchromatin (Jorge,
2005). The nuclear translocation of VEGF
endows the tumour cells with stronger prolifera-
tive ability and increased transcription of pro-
tumourigenic and angiogenic factors. During the
final stages of induction, the expression of VEGF
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sion of VEGF prevailed between areas where
angiogenesis was present and absent. Although
the pituitary VEGF level correlates well with
mass (Cracchiolo, 2002), high serum levels of
VEGF are not a prerequisite, suggesting that
additional factors are involved in this process.
We present the first study examining the expres-
sion of aquaporin-1 in response to DES stimula-
tion, and we evaluate its potential role as a stim-
ulator of angiogenesis and executor of metastasis.
Although it has been reported that transfection of
AQP-1 into the pituitary endocrine cell line AtT-
20 affects dense core secretory granule (DCSG)
biogenesis and normal levels of hormonal secre-
tion (Arnaoutova, 2008), we failed to detect the
expression of AQP-1 in the pituitary cells in both
groups at each time point. In contrast, at week
12, AQP-1 was strongly expressed in the vascular
endothelial cells, suggesting that AQP-1 may
function as an executor of angiogenesis and pos-
sibly indirectly affect cell proliferation, tumour
cell migration,and invasion.AQP1-knockout mice
exhibited reduced tumour angiogenesis, suggest-
ing that AQP-1 facilitates cell migration by
affecting the transport of water to cell protru-
sions formed during migration and that it is,
therefore, a potential therapeutic target to treat
tumours (Verkman, 2005; Hu, 2006;
Papadopoulos, 2008). It was also reported that
AQP-1 was strongly expressed in endothelial cells
of the capillary and postcapillary venules in
Lewis-lung-carcinoma tumour tissues in mice,
which could be inhibited by the mild diuretic
Acetazolamide (Xiang, 2004).
In summary, our results showed progressive
changes in the pituitary gland upon DES treat-
ment. Anatomically, the vault-shape enlargement
of the pituitary gland and the discontinuous CSF
signal in the mid-sagittal section evident upon
MRI strongly suggested that hypophyseal prolif-
eration and angiogenesis resulted from DES
treatment. Non-endothelial hypophyseal VEGF
expression appears to function during angiogenic
initiation, whereas subsequent sustained angio-
genesis may partially rely on the endothelial
expression of AQP-1. Disrupting the action of
VEGF and AQP-1 depending on the stage of
angiogenesis may provide an important therapeu-
tic strategy to control tumour cell growth, both in
vitro and clinically.
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